Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.
Maureen M JonasSusan RheeDeirdre A KellyAntonio Del Valle-SegarraCornelia Feiterna-SperlingSusan GilmourRegino P Gonzalez-PeraltaLoreto HierroDaniel H LeungSimon C LingYuri LobzinSteven J LobrittoTatsuki MizuochiMichael R NarkewiczVishakha SabharwalJessica WenHoi Kei LonJohn MarcinakAndrew ToppRakesh TripathiEtienne M SokalPublished in: Hepatology (Baltimore, Md.) (2022)
A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV-infected children 3 to < 12 years old.